Skip to main content

Closed

MXCT: MaxCyte, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-6.4% / yr

Operating margin-119.7%

ROIC-20.8%

Financially safe

Stretched

Debt / equity0.10×

Interest coverage0.0×

Current ratio12.04×

MaxCyte, Inc.

MXCTNASDAQ·USD·Closed

MaxCyte, Inc.

MXCTNASDAQ·USD·Closed

$1.05

+0.00%

$1.05

+$0.00 (0.00%)

52W Range

26thpctl

Volume

0.38×avg

Mkt Cap

112.48MUSD

P/E

-2.8TTM

Div Yield

–ann

52W Range

26thpctl

Volume

0.38×avg

Market Cap

112.48MUSD

P/E Ratio

-2.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings